Erratum: The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody (Nature Communications (2011) 2 (601) DOI: 10.1038/ncomms1615);The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

Nature Communications

Volumn 2, Issue 1, 2011, Pages

  Douglas, Alexander D ^a   Williams, Andrew R ^a   Illingworth, Joseph J ^a   Kamuyu, Gathoni ^b   Biswas, Sumi ^a   Goodman, Anna L ^a   Wyllie, David H ^a   Crosnier, Cécile ^c   Miura, Kazutoyo ^d   Wright, Gavin J ^c   Long, Carole A ^d   Osier, Faith H ^b   Marsh, Kevin ^b   Turner, Alison V ^a   Hill, Adrian V S ^a   Draper, Simon J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; NEUTRALIZING ANTIBODY; PARASITE ANTIGEN; PLASMODIUM FALCIPARUM RETICULOCYTE BINDING PROTEIN HOMOLOG 5; UNCLASSIFIED DRUG; CARRIER PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN; RH5 PROTEIN, PLASMODIUM FALCIPARUM;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHILD; CONTROLLED STUDY; EXPERIMENTAL RABBIT; FEMALE; GROWTH INHIBITION; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; KENYA; MALARIA FALCIPARUM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; ADENOVIRUS; ANIMAL; BIOSYNTHESIS; BLOOD; CROSS PROTECTION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; ESCHERICHIA COLI; GENE VECTOR; GENETICS; IMMUNOLOGY; MEROZOITE; METABOLISM; PARASITOLOGY; PLASMID; RABBIT; VACCINATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CARRIER PROTEINS; CROSS PROTECTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; ESCHERICHIA COLI; GENETIC VECTORS; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MEROZOITES; MICE; PLASMIDS; PLASMODIUM FALCIPARUM; RABBITS; RECOMBINANT PROTEINS; VACCINATION;

EID: 84455194899     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3355     Document Type: Erratum

References (59)

1. Cohen, J., Nussenzweig, V., Nussenzweig, R., Vekemans, J. & Leach, A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum. Vaccin. 6, 90-96 (2010).
2. Goodman, A. L. & Draper, S. J. Blood-stage malaria vaccines-recent progress and future challenges. Ann. Trop. Med. Parasitol. 104, 189-211 (2010).
3. Holder, A. A. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 136, 1445-1456 (2009).
4. Remarque, E. J., Faber, B. W., Kocken, C. H. & Th omas, A. W. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 24, 74-84 (2008).
5. Lyon, J. A. et al. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One 3, e2830 (2008).
6. Dutta, S. et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One 4, e8138 (2009).
7. Miura, K. et al. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. C lin. Vaccine Immunol. 16, 963-968 (2009).
8. Thera, M. A. et al. A field trial to assess a blood-stage malaria vaccine. N Engl. J. Med. 365, 1004-1013 (2011).
9. Draper, S. J. et al. Effective induction of high-titer antibodies by viral vector vaccines. Nature Med. 14, 819-821 (2008).
10. Forbes, E. K. et al. Combining liver-and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference. J. Immunol. 187, 3738-3750 (2011).
11. Douglas, A. D. et al. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28, 7167-7178 (2010).
12. Biswas, S. et al. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of plasmodium falciparum AMA1. PLoS One 6, e20977 (2011).
13. Goodman, A. L. et al. New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. I nfect. Immun. 78, 4601-4612 (2010).
14. Draper, S. J. et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J. Immunol. 185, 7583-7595 (2010).
15. Sheehy, S. H. et al. Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol. Ther.; Epub 23 Aug 2011, doi:2010.1038 (2011).
16. Collins, W. E. et al. Efficacy of vaccines containing rhoptry-associated proteins RAP1 and RAP2 of Plasmodium falciparum in Saimiri boliviensis monkeys 62, 466-479 (2000).
17. Kushwaha, A., Rao, P. P., Suresh, R. P. & Chauhan, V. S. I mmunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli. Parasite Immunol. 23, 435-444 (2001). (Pubitemid 32863126)
18. Cowman, A. F. & Crabb, B. S. Invasion of red blood cells by malaria parasites. Cell 124, 755-766 (2006). (Pubitemid 43261450)
19. Gilson, P. R. et al. Identification and stoichiometry of GPI-anchored membrane proteins of the human malaria parasite plasmodium falciparum. Mol. Cell. Proteomics 5, 1286-1299 (2006). (Pubitemid 44103399)
20. Jiang, L. et al. Evidence for erythrocyte-binding antigen 175 as a component of a ligand-blocking blood-stage malaria vaccine. Proc. Natl Acad. Sci. USA 108, 7553-7558 (2011).
21. Lopaticki, S. et al. Reticulocyte and erythrocyte binding-like proteins function cooperatively in invasion of human erythrocytes by malaria parasites. Infect. Immun. 79, 1107-1117 (2011).
22. Riglar, D. T. et al. Super-resolution dissection of coordinated events during malaria parasite invasion of the human erythrocyte. Cell Host Microbe 9, 9-20 (2011).
23. Florens, L. et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 419, 520-526 (2002).
24. Baum, J. et al. Reticulocyte-bindinGprotein homologue 5-an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int. J. Parasitol. 39, 371-380 (2009).
25. Th am, W. H. et al. Antibodies to reticulocyte bindinGprotein-like homologue 4 inhibit invasion of Plasmodium falciparum into human erythrocytes. Infect. Immun. 77, 2427-2435 (2009).
26. Duraisingh, M. T. et al. Phenotypic variation of Plasmodium falciparum merozoite proteins directs receptor targeting for invasion of human erythrocytes. EMBO J. 22, 1047-1057 (2003). (Pubitemid 36313589)
27. Gao, X. et al. Antibodies targeting the PfRH1 binding domain inhibit invasion of Plasmodium falciparum merozoites. P LoS Pathog. 4, e1000104 (2008).
28. Pandey, K. C. et al. Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. Mol. Biochem. Parasitol. 123, 23-33 (2002). (Pubitemid 34880088)
29. Rodriguez, M., Lustigman, S., Montero, E., Oksov, Y. & Lobo, C. A. PfRH5: a novel reticulocyte-binding family homolog of plasmodium falciparum that binds to the erythrocyte, and an investigation of its receptor. PLoS One 3, e3300 (2008).
30. Sauerwein, R. W., Roestenberg, M. & Moorthy, V. S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat. Rev. Immunol. 11, 57-64 (2011).
31. Spring, M. D. et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. P LoS One 4, e5254 (2009).
32. Duncan, C. J. et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One 6, e22271 (2011).
33. Hayton, K. et al. Erythrocyte bindinGprotein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe 4, 40-51 (2008). (Pubitemid 351958114)
34. Lobo, C. A., Rodriguez, M., Struchiner, C. J., Zalis, M. G. & Lustigman, S. Associations between defined polymorphic variants in the PfRH ligand family and the invasion pathways used by P. falciparum field isolates from Brazil. Mol. Biochem. Parasitol. 149, 246-251 (2006). (Pubitemid 44279092)
35. Rayner, J. C., Vargas-Serrato, E., Huber, C. S., Galinski, M. R. & Barnwell, J. W. A Plasmodium falciparum homologue of Plasmodium vivax reticulocyte bindinGprotein (PvRBP1) defines a trypsin-resistant erythrocyte invasion pathway. J. Exp. Med. 194, 1571-1581 (2001). (Pubitemid 33126808)
36. Crosnier, C. et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature doi: 10.1038/nature10606. Epub ahead of print (2011).
37. Gomez-Escobar, N. et al. Erythrocyte invasion and merozoite ligand gene expression in severe and mild Plasmodium falciparum malaria. J. Infect. Dis. 201, 444-452 (2010).
38. Mackinnon, M. J. et al. Comparative transcriptional and genomic analysis of Plasmodium falciparum field isolates. P LoS Pathog. 5, e1000644 (2009).
39. Takala, S. L. et al. Short report: rare Plasmodium falciparum merozoite surface protein 1 19-kda (msp-1(19)) haplotypes identified in Mali using highthroughput genotyping methods. Am. J. Trop. Med. Hyg. 76, 855-859 (2007). (Pubitemid 351627668)
40. Volkman, S. K. et al. A genome-wide map of diversity in Plasmodium falciparum. Nat. Genet. 39, 113-119 (2007). (Pubitemid 46026510)
41. Jeffares, D. C. et al. Genome variation and evolution of the malaria parasite Plasmodium falciparum. Nat. Genet. 39, 120-125 (2007). (Pubitemid 46026511)
42. Freeman, R. R., Trejdosiewicz, A. J. & Cross, G. A. Protective monoclonal antibodies recognising stage-specific merozoite antigens of a rodent malaria parasite. Nature 284, 366-368 (1980). (Pubitemid 10122195)
43. Crompton, P. D. et al. A prospective analysis of the Ab response to Plasmodium falciparum before and aft er a malaria season by protein microarray. Proc. Natl Acad. Sci. USA 107, 6958-6963 (2010).
44. Fowkes, F. J., Richards, J. S., Simpson, J. A. & Beeson, J. G. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. P LoS Med. 7, e1000218 (2010).
45. Gardner, M. J. et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498-511 (2002).
46. Oeuvray, C. et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84, 1594-1602 (1994). (Pubitemid 24273030)
47. Coppel, R. L. Vaccinating with the genome: a Sisyphean task? T rends Parasitol. 25, 205-212 (2009).
48. Triglia, T. et al. Identification of proteins from Plasmodium falciparum that are homologous to reticulocyte bindinGproteins in Plasmodium vivax. Infect. Immun. 69, 1084-1092 (2001). (Pubitemid 32109576)
49. Alcock, R. et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci. Transl. Med. 2, 19ra12 (2010).
50. Reyes-Sandoval, A. et al. Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect. Immun. 78, 145-153 (2010).
51. Sridhar, S. et al. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J. Virol. 82, 3822-3833 (2008). (Pubitemid 351521219)
52. Stanton, R. J., McSharry, B. P., Armstrong, M., Tomasec, P. & Wilkinson, G. W. G. Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques 45, 659-662 (2008).
53. Draper, S. J. et al. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody-and T cell-mediated multistage protection against malaria. Cell Host Microbe 5, 95-105 (2009).
54. Kaneko, O., Mu, J., Tsuboi, T., Su, X. & Torii, M. G ene structure and expression of a Plasmodium falciparum 220-kDa protein homologous to the Plasmodium vivax reticulocyte bindinGproteins. Mol. Biochem. Parasitol. 121, 275-278 (2002). (Pubitemid 34606009)
55. Bushell, K. M., Sollner, C., Schuster-Boeckler, B., Bateman, A. & Wright, G. J. Large-scale screening for novel low-affinity extracellular protein interactions. Genome Res. 18, 622-630 (2008). (Pubitemid 351482786)
56. de Cassan, S. C. et al. The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J. Immunol. 187, 2602-2616 (2011).
57. Marsh, K. & Kinyanjui, S. Immune effector mechanisms in malaria. Parasite Immunol. 28, 51-60 (2006).
58. Osier, F. H. et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect. Immun. 76, 2240-2248 (2008). (Pubitemid 351656161)
59. Miura, K. et al. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. V accine 26, 193-200 (2008). (Pubitemid 350266126)